Brian Gastman, MD, Cleveland Clinic

home / authors / brian-gastman-md-cleveland-clinic

Articles

Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C Melanoma

July 12th 2023

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.

Emerging Treatments for Advanced Melanoma

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Long-Term Survival Data in Adjuvant Therapy

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Metastatic Melanoma Long-Term Survival Data

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

BRAF-Wild Type vs Mutated Unresectable Melanoma

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Short-Term COVID-19 NCCN Recommendations

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Balancing Safety and Efficacy in Adjuvant Therapy

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Adjuvant Therapy in Stage IIIB/IIIC/IIID Melanoma

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Adjuvant Clinical Trial Data Impact on Treatment Selection

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Importance of Molecular Testing in Stage III Melanoma

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Neoadjuvant Melanoma Therapy: Patient Selection

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Impact of MSLT-II Data on Completion Lymph Node Dissection

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

The Optimal Approach to Treating Advanced Melanoma

Brian Gastman, MD, Cleveland Clinic;Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512